Last reviewed · How we verify
Budesonide extrafine pMDI
Budesonide extrafine pMDI is a corticosteroid that works by reducing inflammation in the lungs.
Budesonide extrafine pMDI is a corticosteroid that works by reducing inflammation in the lungs. Used for Maintenance treatment of asthma, Maintenance treatment of COPD.
At a glance
| Generic name | Budesonide extrafine pMDI |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
It does this by binding to glucocorticoid receptors, which then decrease the production of pro-inflammatory cytokines and increase the production of anti-inflammatory cytokines. This leads to a reduction in airway inflammation and improved symptoms in patients with asthma and COPD.
Approved indications
- Maintenance treatment of asthma
- Maintenance treatment of COPD
Common side effects
- Oral thrush
- Headache
- Cough
- Upper respiratory tract infection
- Bronchitis
Key clinical trials
- Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (PHASE3)
- Cross-over Study to Evaluate the Effect on Trough Forced Expiratory Volume in One Second (FEV1) After 4 Weeks Treatment With CHF 5188 pMDI qd in Adult Patients With Persistent Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |